No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Amylin, a satiety hormone, has been identified as a potential ... Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of ...

GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

Amylin, a satiety hormone ... Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Morningstar brands and products Company Portfolio ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

Amylin is produced in the pancreatic beta cells ... please visit www.zealandpharma.com. This press release contains “forward-looking statements”, as that term is defined in the Private ...

Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...